ORKAOruka Therapeutics, Inc.
Price
+428%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 2% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for ORKA today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (“PsO”) and other inflammatory and immunology (“I&I”) indications. Our name is derived from or, for “skin,” and arukah, for “restoration,” and reflects our mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk.
In the company’s own words · 10-K filed Mar 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 9, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 24, 2026On July 22, 2026, Oruka Therapeutics, Inc. entered into a letter agreement with Todd Edwards pursuant to which Mr. Edwards commenced employment as Chief Commercial Officer on August 24, 2026.Director or officer change · Form 8-K
- Aug 10, 2026Oruka Therapeutics Reports Second Quarter 2026.Earnings release · press release
- Jun 1, 2026On May 29, 2026, Oruka Therapeutics, Inc. (the “Company”) entered into the First Amendment to IL-23 License Agreement (the “Amendment”), amending the IL-23 License Agreement dated as of December 17, 2024 (the “License Agreement”), by and between the Company and Paragon Therapeutics, Inc. (“Paragon”)Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.